首页> 美国卫生研究院文献>ESMO Open >Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

【2h】

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

机译：二线Cabozantinib索拉芬皮治疗晚期肝细胞癌：第3期天体试验的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

In the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated cabozantinib in patients who had received sorafenib as the only prior systemic therapy.

机译：在3阶段，Cabozantinib与先前治疗的晚期肝细胞癌（HCC）的安慰剂相比，Cabozantinib改善了整体存活（OS）和无进展的存活（PFS）。该亚组分析评估了将Sorafenib作为唯一的先前全身治疗的患者中的CaCozantib。

著录项

期刊名称 ESMO Open
作者
Robin Kate Kelley; Baek-Yeol Ryoo; Philippe Merle; Joong-Won Park; Luigi Bolondi; Stephen L Chan; Ho Yeong Lim; Ari D Baron; Francis Parnis; Jennifer Knox; Stéphane Cattan; Thomas Yau; Julie C Lougheed; Steven Milwee; Anthony B El-Khoueiry; Ann-Lii Cheng; Tim Meyer; Ghassan K Abou-Alfa;
展开▼
作者单位

展开▼
年(卷),期 2020(5),4
年度 2020
页码 e000714
总页数 9
原文格式 PDF
正文语种
中图分类
关键词

机译：肝细胞癌;酪氨酸激酶抑制剂;Cabozantib;索拉非尼;

相似文献

外文文献
中文文献
专利

1. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial [J] . Zhu Andrew X., Park Joon Oh, Ryoo Baek-Yeol, The lancet oncology . 2015,第7期

机译：索拉非尼（REACH）一线治疗后的晚期肝细胞癌患者接受雷莫昔单抗和安慰剂作为二线治疗：一项随机，双盲，多中心，3期试验
2. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial [J] . Kudo Masatoshi, Hatano Etsuro, Ohkawa Shinichi, Journal of gastroenterology . 2017,第4期

机译：RAMUCILUMAB作为肝细胞癌晚期患者的二线治疗：日本亚群分析达重试验
3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial [J] . MotzerR.J., EscudierB., TomczakP., The lancet oncology . 2013,第6期

机译：阿昔替尼vs索拉非尼作为晚期肾细胞癌的二线治疗：总体生存分析和一项随机3期试验的更新结果
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Poly(lactide-co-glycolide) Microspheres for Localized, Magnetic Resonance Imaging Monitored, Transcatheter Delivery of Sorafenib to Hepatocellular Carcinoma. [D] . Chen, Jeane. 2015

机译：聚（丙交酯-共-乙交酯）微球体用于局部监测，磁共振成像监测，索拉非尼经导管输送至肝细胞癌。
6. Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials [O] . Hui Wang, Hefang Wang, Zhichong Yu, 2018

机译：索拉非尼在晚期肝细胞癌患者中的替代治疗策略：随机III期临床试验的荟萃分析
7. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial [O] . RobinKate Kelley, Baek-Yeol Ryoo, Philippe. Merle, 2020

机译：二线Cabozantinib索拉芬皮治疗晚期肝细胞癌：第3期天体试验的亚组分析

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

摘要

著录项

相似文献

相关主题

期刊订阅